Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

GOCO vs ABEO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABEO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 10–0 Matrix Metrics)

ABEO Overall Winner 6-Pillar Tally: GOCO 1 – 4 ABEO (1 Tie) Matrix Metrics: GOCO 0 – 10 ABEO

As of Nov 17, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over GoHealth, Inc. (GOCO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GOCO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.30 (N/M Forward P/E, -292.0% operating margin), whereas ABEO carries 44.1/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin).

  • Technical & Structure Timing Caution: GOCO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.9); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GOCO vs ABEO
GOCO NASDAQ
GoHealth, Inc. Class A Common Stock
Insurance Agents, Brokers & Service
$0.30
+5.14% 1D
Market Cap $8.5M
TTM Revenue $153M
Forward P/E N/M
Beta / 30D Vol 2.15β · 201% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 48.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -32.2%), weak momentum, RSI 24
RSI-14: 23.9 · SMA20: $0.59 · SMA50: $0.88
ABEO NASDAQ Head-to-Head Winner
Abeona Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.60
-0.19% 1D
Market Cap $149.2M
TTM Revenue $39M
Forward P/E 18.7x
Beta / 30D Vol 0.60β · 145% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.9%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $3.68 · SMA50: $4.57

6-Pillar Scorecard Institutional Category Breakdown (GOCO 1 – 4 ABEO)

Columns: Metric · GOCO · ABEO
1. Valuation Multiples ABEO
Forward P/E N/M 18.7x
Trailing P/E N/M 18.7x
PEG Ratio N/M N/M
EV / Revenue 0.1x 2.6x
2. Growth & Scale ABEO
Revenue Growth (YoY) -94.6% +2745.0%
Earnings Growth (YoY) +424.1% +0.0%
TTM Revenue (USD) $153M $39M
Market Cap $8.5M $149.2M
3. Profitability & Quality ABEO
Gross Margin 57.3% -3.5%
Operating Margin -292.0% -186.1%
Net Profit Margin -189.7% -160.3%
Return on Equity (ROE) -289.9% -42.1%
4. Balance Sheet & Cash Flow ABEO
Cash Generation (TTM) -$148M EBITDA -$66M
Cash Flow Margin -96.9% EBITDA Mgn N/A
Net Cash / Leverage $0.13 Book/Sh · -289.9% ROE $50M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GOCO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 165.8% (27th %ile)
Put/Call OI Skew N/A 0.71x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Insurance Brokers Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GOCO (0) vs ABEO (10)
Institutional Metric GOCO ABEO Criterion Row Edge
Market Capitalization
Scale
$8.5M $149.2M Larger Scale ABEO
Trailing P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Forward P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Revenue Growth (YoY)
Growth
-94.6% +2745.0% Higher Growth ABEO
Operating Margin (TTM)
Profitability
-292.0% -186.1% Higher Margin ABEO
Net Profit Margin
Profitability
-189.7% -160.3% Higher Margin ABEO
Return on Equity (ROE)
Capital Efficiency
-289.9% -42.1% Higher ROE ABEO
52-Week Range Position
Momentum
0% ($0–$7) 9% ($2–$8) Stronger Trend ABEO
Beta / 30D Volatility
Risk Regime
2.15β · 201% Vol 0.60β · 145% Vol Lower Realized Risk ABEO
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 44.1 / 100 (HOLD) Higher Composite ABEO
Trailing 12M Revenue (USD)
Operating Scale
$153M $39M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
57.3% -3.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$148M EBITDA ($0.13 Book/Sh · -289.9% ROE) -$66M ($50M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABEO +65.94 pp
GOCO: -64.69% · ABEO: +1.25%
3M Horizon ABEO +96.07 pp
GOCO: -81.52% · ABEO: +14.55%
6M Horizon ABEO +93.28 pp
GOCO: -90.56% · ABEO: +2.72%
1Y Horizon ABEO +115.39 pp
GOCO: -87.97% · ABEO: +27.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GOCO vs ABEO. Trailing 12-month operating profitability (GOCO -292.0% vs ABEO -186.1%) and valuation multiples (GOCO N/M vs ABEO 18.7x Forward P/E) are benchmarked directly in Pillar 4 below.

GOCO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$153M
Gross Margin57.3%
Op. Margin-292.0%
ROE / Fwd P/E-289.9% · N/M
ABEO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$39M
Gross Margin-3.5%
Op. Margin-186.1%
ROE / Fwd P/E-42.1% · 18.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GOCO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GOCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABEO BREAKDOWN
68d in phase · OBV DISTRIBUTION
Current IV 165.8%
IV Percentile 27th %ile
Put/Call OI Skew 0.71x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GOCO Moat Profile Cyclical / Execution-Driven Positioning
Insurance Brokers Operator
Competes within the Insurance Brokers value chain with $8.5M market capitalization and -292.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABEO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $149.2M market capitalization and -186.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GOCO vs ABEO Key Questions & Quantitative Answers

As of Nov 17, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over GoHealth, Inc. (GOCO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GOCO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.30 (N/M Forward P/E, -292.0% operating margin), whereas ABEO carries 44.1/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin). Technical & Structure Timing Caution: GOCO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.9); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABEO leads the Growth & Scale pillar: GOCO posts -94.6% YoY revenue growth and +424.1% YoY earnings growth on $153M TTM revenue (57.3% gross margin, -292.0% operating margin), compared with ABEO at +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin). On trailing 12-month operating scale, GOCO generates $153M in USD-normalized revenue versus $39M for ABEO. In operating R&D and SG&A reinvestment, GOCO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABEO.

ABEO screens cheaper on headline valuation multiples. GOCO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-96.9% EBITDA margin), whereas ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GOCO (-289.9% ROE) versus ABEO (-42.1% ROE) capital efficiency.

In options market volatility and institutional positioning, GOCO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.15β · 201% Vol realized risk). By comparison, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.71x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 145% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.